Geneva Pharmaceuticals Technology Corporation Sustainability Profile
Geneva Pharmaceuticals Technology Corporation, commonly referred to as Geneva Pharmaceuticals, is a leading player in the pharmaceutical industry, headquartered in the United States. Founded in the early 2000s, the company has established a strong presence in key operational regions, focusing on the development and manufacturing of high-quality generic and specialty pharmaceuticals. With a commitment to innovation, Geneva Pharmaceuticals offers a diverse portfolio of products, including advanced formulations and delivery systems that set them apart in the market. Their dedication to quality and compliance has earned them a reputable position within the industry, marked by significant milestones in regulatory approvals and product launches. As a trusted partner in healthcare, Geneva Pharmaceuticals continues to contribute to improved patient outcomes through accessible and effective medication solutions.
DitchCarbon Score
How does Geneva Pharmaceuticals Technology Corporation's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Geneva Pharmaceuticals Technology Corporation's score of 45 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Geneva Pharmaceuticals Technology Corporation, headquartered in the US, currently does not have specific carbon emissions data available for the most recent year. The company is a current subsidiary of Sandoz Group AG, and any emissions data or climate commitments would be inherited from this parent organisation. As of now, Geneva Pharmaceuticals has not set specific reduction targets or initiatives under the Science Based Targets initiative (SBTi) or other climate pledges. The absence of documented reduction targets suggests that the company may still be in the early stages of formalising its climate commitments. Given its affiliation with Sandoz Group AG, any relevant emissions data or climate strategies would be derived from the parent company's initiatives. However, without specific figures or commitments from Sandoz, it is challenging to provide a detailed overview of Geneva Pharmaceuticals' carbon footprint or climate action plans. In summary, while Geneva Pharmaceuticals Technology Corporation is part of a larger corporate family with potential climate initiatives, it currently lacks specific emissions data and reduction commitments.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| Scope 1 | 75,620,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 158,430,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | 0,000,000,000 | 0,000,000,000 |
How Carbon Intensive is Geneva Pharmaceuticals Technology Corporation's Industry?
How Carbon Intensive is Geneva Pharmaceuticals Technology Corporation's Location?
Geneva Pharmaceuticals Technology Corporation's Scope 3 Categories Breakdown
Geneva Pharmaceuticals Technology Corporation's Scope 3 emissions, which decreased by 15% last year and decreased by approximately 15% since 2023, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 69% of Scope 3 emissions.
Top Scope 3 Categories
Geneva Pharmaceuticals Technology Corporation's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Geneva Pharmaceuticals Technology Corporation has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
